Published in final edited form as:

Med Hypotheses. 2018 November ; 120: 72–75. doi:10.1016/j.mehy.2018.08.019.

Are sleep continuity disturbance and fatigue prodromal symptoms of cancer development?

Sheila N. Garland, PhD¹, Michael R. Irwin, MD², Donn Posner, PhD³, and Michael L. Perlis, PhD⁴

¹Departments of Psychology and Oncology, Memorial University, 232 Elizabeth Avenue, St. John's Newfoundland, Canada. A1B 3X9

²Cousins Center for Psychoneuroimmunology at the UCLA Semel Institute for Neuroscience, and the Departments of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, 300 UCLA Medical Plaza #3109, Los Angeles, CA 90095

³Psychiatry and Behavioral Sciences, Stanford University School of Medicine, 401 Quarry Road, Stanford, CA 94305-5717

⁴Behavioral Sleep Medicine Program, Department of Psychiatry, University of Pennsylvania, 3535 Market Street, Suite 670, Philadelphia, PA 19104

Abstract

Sleep continuity disturbance (also known as insomnia) and fatigue are common complaints of individuals diagnosed with cancer. Traditionally, many have believed that sleep continuity disturbance and fatigue are caused, in large measure, by the impact of the cancer diagnosis and treatment. Recent prospective research suggests however, that sleep continuity disturbance and fatigue may actually precede a cancer diagnosis. We suggest that sleep continuity disturbance and fatigue may in fact represent prodromal symptoms of cancer. We review the current perspectives of this sequence of events and present a revised schematic that accounts for the role of biological, behavioural, and cognitive factors that contribute to the development and maintenance of sleep continuity disturbances in cancer patients. Monitoring emergent and unexplained patient-reported fatigue, sleepiness, and insomnia may serve as early warning signs of new onset cancer, providing opportunity for early detection and early intervention.

Keywords

Insomnia; Fatigue; Sleep Disturbance; Cancer; Prodrome

Relative to the general population, sleep continuity disturbance (i.e., insomnia) occurs disproportionality in individuals diagnosed with cancer. Prevalence rates for insomnia (problems falling and staying sleep) in individuals with cancer range from 30–60%,

Corresponding Author: Sheila N. Garland, PhD, Department of Psychology, Memorial University of Newfoundland, 232 Elizabeth Avenue, St. John's, Newfoundland, A1B 3X9, Phone: 709-864-4897; Fax: 709-864-2430, sheila.garland@mun.ca.

Conflict of Interest Declaration

The authors declare that they have no conflicts of interest related to this submission.

depending on the definition, time of assessment and measurement tool used.^{1,2} The common belief is that the sleep continuity disturbance and daytime fatigue experienced in individuals diagnosed with cancer are iatrogenic, caused in part by the psychological impact of the diagnosis and the physiological consequences of the treatments used to slow or halt the disease.² With respect to treatment, the therapies most likely to precipitate insomnia and fatigue appear to be chemotherapy and endocrine treatments.^{3,4} This original perspective is represented schematically (Figure 1).

As face valid as the above perspective may be, there is emerging evidence to suggest that sleep and circadian abnormalities occur prior to the initiation of cancer treatment.^{5,6} For example, in one study, patients reported an average insomnia duration of 6.8 years and an average cancer duration of 3.2 years.⁷ Sleep and circadian disruption, attributed to shift work, insomnia, or other sleep disruption, has been implicated in a number of types including breast, prostate, colorectal, and thyroid cancers.^{8–10} The strength of the evidence for the impact of sleep and circadian disruption and inappropriately timed light exposure on tumor growth in animal models led the World Health Organization to classify shift work it as a “probable carcinogen”.¹¹ Collectively, these findings suggest that sleep continuity disturbance may not only be a consequence of the cancer diagnosis and treatment but may also represent a risk factor for the development of the disease or be the activating trigger for tumorigenesis.^{12,13}

In contrast, a number of other prospective cohort studies, have not found an association between sleep and circadian disturbance, sleep duration, sleep quality, or insomnia and incident cancer;¹⁴ however, the research has been heavily criticized for variable definition and measurement of sleep. In an attempt to understand these conflicting results, Erren and colleagues conducted meta-analyses of sleep and cancer incidence among more than 1,500,000 study individuals across 13 countries.¹⁵ While they failed to find a clear answer to the question of “*How are sleep and cancer linked in humans?*” they did conclude that a relationship is chronobiologically plausible, complex, and presumably multidirectional.

We suggest that one possible reason for the conflicting results is that the research to date has largely overlooked the possibility that sleep continuity disturbance is associated with, or a consequence of, a disease process that is already underway, and as such may represent a prodromal sign of cancers that are yet to be diagnosed. There is a growing body of literature demonstrating that sleep and circadian disruption is reciprocally associated with inflammation,¹⁶ with evidence that sleep disturbance can activate inflammatory signaling. These inflammatory cytokines have countervailing influences and are associated with disruption of sleep maintenance and loss of sleep depth, which together induce a vicious feed forward feedback cycle.¹⁷

How might activation of inflammation be initiated to lead to disturbances of sleep? Activation of innate immunity solid tumorigenesis is one likely pathway.¹⁸ As the growing tumor damages normal tissue, inflammatory repair systems are activated and further exacerbate tumor progression, which together lead to the expression of certain inflammatory cytokines such as interleukin-6 that in turn induces C-reactive protein (CRP). These cytokines recruit neutrophils and macrophages to the disease site, which release additional

inflammatory molecules, amplifying the immune response. As long as there is no anti-tumor immunity, this inflammatory process becomes exaggerated, further instigating cancer invasion. Additionally, such release of inflammatory cytokines and increases in systemic inflammation (i.e., CRP) in response to invading tumor cells, is known to induce sleep disturbance as well as a number of other behavioral symptoms, one of the most noticeable being profound fatigue.¹⁹

The association between the activation of innate immunity and fatigue has been documented in other chronic diseases, such as chronic fatigue syndrome^{20,21} but has not been fully explored in the context of early tumorigenesis, although extensive evidence had demonstrated that inflammation is associated with fatigue in cancer survivors.^{19,22,23} Anemia, associated with internal bleeding, may also contribute to the experience of fatigue, and such anemia can lead to the development of occult restless legs syndrome and periodic leg movements of sleep (PLMS).²⁴ In this case, unexplained fatigue and/or sleepiness are thought to result from the sleep fragmenting effects of PLMS. In either case (activation of innate immunity or anemia related PLMs or both), the experience of disabling fatigue may serve as a false cue to the individual that they require more sleep.

Although there are many different conceptualizations of fatigue that depend on the patient group affected, in general fatigue can be defined as a subjective sensation (perceived fatigue) and as an objective and quantifiable change in performance (fatigability).^{25–27} Fatigue also has a temporal component which can be used to distinguish “normal” transient acute fatigue and persistent fatigue.²⁸ Transient acute fatigue tends to be time limited and of mild to moderate severity. While transient fatigue makes daily functioning harder, it can be managed and worked through, and it is typically responsive to increased sleep and/or caffeine or stimulants.²⁸ In contrast, fatigue associated with cancer development is not time limited, is of extreme severity (daily functioning is impaired, cannot be managed with sleep, and/or caffeine or stimulants), is persistent throughout the day, and cannot be tied to health behaviors.

Despite having different pathophysiological origins, both transient and persistent fatigue is often confused with sleepiness in patients, clinicians, and researchers.²⁹ Without awareness of the disease processes underway, this lack of attributional clarity may prompt the individual to think, “I am tired (aka, fatigued). I must, therefore, need more sleep”. Thus, a likely and understandable behavioral response to the experience of profound fatigue is for the individual to attempt to increase sleep opportunity (i.e., sleep expansion). These efforts take the form of napping during the day, going to bed earlier at night, and staying in bed later in the morning. Such sleep extension may result in increased total sleep time, if it is within the individual’s ability to achieve more sleep.

In the case of new onset cancer, the fatigue may not be related to sleep loss and thus no amount of increased sleep time (even if it is within the individual’s ability to substantially increase their total sleep time) will diminish the experience of fatigue. This all but ensures that the patient with new onset cancer will continue to expand sleep opportunity (as a counter fatigue strategy) until there is a mismatch between sleep opportunity and sleep ability, thus increasing the likelihood that insomnia occurs (including decreased sleep

efficiency, potentially diminished slow wave sleep, and dysregulation of the homeostatic mechanisms which control sleep).^{30,31}

Finally, as the insomnia becomes more frequent and/or severe, it is likely that other standard perpetuating factors may also come into play and serve to transition insomnia that occurs with new onset cancer into Insomnia Disorder, including (but not limited to) insomnia attention related bias,³² increased sleep effort,³³ and brain physiology changes that are posited to occur with conditioned activation.³⁴ This revised perspective of the sequence of events is represented schematically (Figure 2).

The implication of this revised perspective is that fatigue and insomnia occur early on in the development of cancer and likely long prior to the diagnosis and treatment of the disease. Our hypothesis that unexplained fatigue and sleep disturbance may be a marker of ongoing cancer onset, which is temporally distinct from the one posited in prior epidemiologic studies, namely, that sleep disruption a risk factor of future cancer onset.³⁵ Although there are no clear-cut points available yet,³⁶ one could postulate that sleep disturbances that occur 10–15+ years before cancer detection, are more likely to represent a risk factor than a marker of underlying disease development, whereas sleep disturbances that occur 2–5 years before tumor detection may hint more toward an underlying disease. Further, there is accumulating and compelling evidence that health behaviors such as smoking, exercise, and alcohol consumption can impact cancer onset,³⁷ hence acting as confounders of the association between sleep/fatigue and cancer initiation. For example, fatigue and sleep continuity disturbance may limit the energy one has to be physically active which may increase cancer risk, hence acting as mediators of the hypothesized associations.

If it can be shown in prospective studies that the hypothesized sequence of events occurs as stipulated, this suggests that monitoring emergent and unexplained patient-reported fatigue, sleepiness, and insomnia may serve as early warning signs of tumorigenesis and new onset cancer, which in turn provide a critical opportunity for early detection and treatment.

Once fatigue and sleep disturbance are identified, what strategies might be used to interrogate the possibility of an underlying cancer? One non-specific strategy could include the evaluation of inflammation,³⁸ with measurement of circulating levels of CRP, a widely available marker of systemic inflammation. If inflammation is elevated, possibly into the high risk category of >3.0 pg/ml,³⁹ then this would point to a biologically plausible pathway underlying or associated with sleep disturbance and/or fatigue. Following this non-specific strategy, a more specific approach could be used, namely, the use of “liquid biopsies”.⁴⁰ Such liquid biopsies provide an analysis of the presence of circulating tumor cells, circulating tumor DNA, or tumor-derived extracellular vesicles, which have been shed from tumors and their metastatic sites into the blood.⁴¹ These techniques have been applied with varying levels of success for the early detection of some of the most deadly cancers including lung,⁴² gastric,⁴³ ovarian,⁴⁴ breast,⁴⁵ and pancreatic.⁴⁶ The liquid biopsies, however, are still mired by several technical challenges and their clinical utility has not yet been firmly established.⁴⁷ Despite this, using these biomarkers are clearly the new direction in early detection of cancer.

Before the proposed model can be effectively tested, the following actions are needed. First, sleep must be assessed in a sensitive and standardized manner.⁴⁸ Erren et al. propose eight possible research recommendations that provide a strong starting point.¹⁵ In addition to the homogenization of how we assess sleep, these recommendations also include the consideration of chronotype, the measurement of not only how long or how “good/bad” we sleep but also when, and the use of statistical methods to assess the accumulation, or overall dose, of sleep disruption over many years. Second, the science must advance to the point that assessment of systematic inflammation and or liquid biopsies are available for widespread use. Lastly, clinicians and patients must be aware of the importance and relevance of sleep as a proxy for overall health. To this end, some have called for sleep to be included in the list of vital signs routinely assessed in clinical settings.^{49,50} Self-reported health has been repeatedly demonstrated to predict morbidity and mortality.⁵¹ Perhaps it also follows that self-reported fatigue and sleep disturbances represent a sensitive marker of an underlying pathology. Routine sleep screening could represent the first step in a comprehensive approach to early cancer detection and potentially improved survival for millions of people around the world.

References

1. Palesh OG, Roscoe JA, Mustian KM, et al. Prevalence, demographics, and psychological associations of sleep disruption in patients with cancer: University of Rochester Cancer Center-Community Clinical Oncology Program. *J Clin Oncol* 2010;28(2):292–298. [PubMed: 19933917]
2. Savard J, Ivers H, Villa J, Caplette-Gingras A, Morin CM. Natural course of insomnia comorbid with cancer: an 18-month longitudinal study. *J Clin Oncol* 2011;29(26):3580–3586. [PubMed: 21825267]
3. Savard J, Liu L, Natarajan L, et al. Breast cancer patients have progressively impaired sleep-wake activity rhythms during chemotherapy. *Sleep* 2009;32(9):1155–1160. [PubMed: 19750920]
4. Savard J, Hervouet S, Ivers H. Prostate cancer treatments and their side effects are associated with increased insomnia. *Psychooncology* 2013;22(6):1381–1388. [PubMed: 22888075]
5. Miaskowski C, Lee K, Dunn L, et al. Sleep-wake circadian activity rhythm parameters and fatigue in oncology patients before the initiation of radiation therapy. *Cancer Nurs* 2011;34(4):255–268. [PubMed: 21252646]
6. Ancoli-Israel S, Liu L, Marler MR, et al. Fatigue, sleep, and circadian rhythms prior to chemotherapy for breast cancer. *Support Care Cancer* 2006;14(3):201–209. [PubMed: 16010529]
7. Garland SN, Carlson LE, Stephens AJ, Antle MC, Samuels C, Campbell TS. Mindfulness-based stress reduction compared with cognitive behavioral therapy for the treatment of insomnia comorbid with cancer: a randomized, partially blinded, noninferiority trial. *J Clin Oncol* 2014;32(5):449–457. [PubMed: 24395850]
8. Sen A, Opdahl S, Strand LB, Vatten LJ, Laugsand LE, Janszky I. Insomnia and the Risk of Breast Cancer: The HUNT Study. *Psychosom Med* 2017;79(4):461–468. [PubMed: 27763987]
9. Fang HF, Miao NF, Chen CD, Sithole T, Chung MH. Risk of Cancer in Patients with Insomnia, Parasomnia, and Obstructive Sleep Apnea: A Nationwide Nested Case-Control Study. *J Cancer* 2015;6(11):1140–1147. [PubMed: 26516362]
10. Smolensky MH, Hermida RC, Reinberg A, Sackett-Lundeen L, Portaluppi F. Circadian disruption: New clinical perspective of disease pathology and basis for chronotherapeutic intervention. *Chronobiol Int* 2016;33(8):1101–1119. [PubMed: 27308960]
11. Straif K, Baan R, Grosse Y, et al. Carcinogenicity of shift-work, painting, and fire-fighting. *Lancet Oncol* 2007;8(12):1065–1066. [PubMed: 19271347]
12. Uth K, Sleigh R. Deregulation of the circadian clock constitutes a significant factor in tumorigenesis: a clockwork cancer. Part I: clocks and clocking machinery. *Biotechnol Biotechnol Equip* 2014;28(2):176–183. [PubMed: 26019503]

13. Uth K, Sleight R. Deregulation of the circadian clock constitutes a significant factor in tumorigenesis: a clockwork cancer. Part II. In vivo studies. *Biotechnol Biotechnol Equip* 2014;28(3):379–386. [PubMed: 26019524]
14. Vogtmann E, Levitan EB, Hale L, et al. Association between sleep and breast cancer incidence among postmenopausal women in the Women's Health Initiative. *Sleep* 2013;36(10):1437–1444. [PubMed: 24082303]
15. Erren TC, Morfeld P, Foster RG, Reiter RJ, Gross JV, Westermann IK. Sleep and cancer: Synthesis of experimental data and meta-analyses of cancer incidence among some 1,500,000 study individuals in 13 countries. *Chronobiol Int* 2016;33(4):325–350. [PubMed: 27003385]
16. Irwin MR, Olmstead R, Carroll JE. Sleep Disturbance, Sleep Duration, and Inflammation: A Systematic Review and Meta-Analysis of Cohort Studies and Experimental Sleep Deprivation. *Biol Psychiatry* 2016;80(1):40–52. [PubMed: 26140821]
17. Irwin MR, Opp MR. Sleep Health: Reciprocal Regulation of Sleep and Innate Immunity. *Neuropsychopharmacology* 2017;42(1):129–155. [PubMed: 27510422]
18. Munn LL. Cancer and inflammation. *Wiley Interdiscip Rev Syst Biol Med* 2017;9(2).
19. Bower JE, Ganz PA, Irwin MR, Kwan L, Breen EC, Cole SW. Inflammation and behavioral symptoms after breast cancer treatment: do fatigue, depression, and sleep disturbance share a common underlying mechanism? *J Clin Oncol* 2011;29(26):3517–3522. [PubMed: 21825266]
20. Lorusso L, Mikhaylova SV, Capelli E, Ferrari D, Ngonga GK, Ricevuti G. Immunological aspects of chronic fatigue syndrome. *Autoimmun Rev* 2009;8(4):287–291. [PubMed: 18801465]
21. Aoki R, Kobayashi N, Suzuki G, et al. Human herpesvirus 6 and 7 are biomarkers for fatigue, which distinguish between physiological fatigue and pathological fatigue. *Biochem Biophys Res Commun* 2016;478(1):424–430. [PubMed: 27396623]
22. Bower JE. Behavioral symptoms in patients with breast cancer and survivors. *J Clin Oncol* 2008;26(5):768–777. [PubMed: 18258985]
23. Collado-Hidalgo A, Bower JE, Ganz PA, Cole SW, Irwin MR. Inflammatory biomarkers for persistent fatigue in breast cancer survivors. *Clin Cancer Res* 2006;12(9):2759–2766. [PubMed: 16675568]
24. DeLoughery TG. Iron Deficiency Anemia. *Med Clin North Am* 2017;101(2):319–332. [PubMed: 28189173]
25. Finsterer J, Mahjoub SZ. Fatigue in healthy and diseased individuals. *Am J Hosp Palliat Care* 2014;31(5):562–575. [PubMed: 23892338]
26. Barsevick A, Frost M, Zwinderman A, Hall P, Halyard M, Consortium G. I'm so tired: biological and genetic mechanisms of cancer-related fatigue. *Qual Life Res* 2010;19(10):1419–1427. [PubMed: 20953908]
27. Barsevick AM, Irwin MR, Hinds P, et al. Recommendations for high-priority research on cancer-related fatigue in children and adults. *J Natl Cancer Inst* 2013;105(19):1432–1440. [PubMed: 24047960]
28. Jason LA, Evans M, Brown M, Porter N. What is fatigue? Pathological and nonpathological fatigue. *PM R* 2010;2(5):327–331. [PubMed: 20656613]
29. Mairesse O, Neu D. Tired of blunt tools? Sharpening the clinical assessment of fatigue and sleepiness. *Psychiatry Res* 2016;238:100–108. [PubMed: 27086218]
30. Skorucak J, Arbon E, Dijk DJ, Achermann P. Response to chronic sleep restriction, extension, and total sleep deprivation in humans: adaptation or preserved sleep homeostasis? *Sleep* 2018.
31. Vallieres A, Cklic T, Bastien CH, Espie CA. A preliminary evaluation of the physiological mechanisms of action for sleep restriction therapy. *Sleep Disord* 2013;2013:726372. [PubMed: 24349793]
32. Harvey AG. A cognitive model of insomnia. *Behav Res Ther* 2002;40(8):869–893. [PubMed: 12186352]
33. Espie CA, Broomfield NM, MacMahon KM, Macphee LM, Taylor LM. The attention-intention-effort pathway in the development of psychophysiological insomnia: a theoretical review. *Sleep Med Rev* 2006;10(4):215–245. [PubMed: 16809056]

34. Perlis ML, Giles DE, Mendelson WB, Bootzin RR, Wyatt JK. Psychophysiological insomnia: the behavioural model and a neurocognitive perspective. *J Sleep Res* 1997;6(3):179–188. [PubMed: 9358396]
35. Blask DE. Melatonin, sleep disturbance and cancer risk. *Sleep Med Rev* 2009;13(4):257–264. [PubMed: 19095474]
36. Erren TC, Gross JV, Lewis P. Computing sleep deficiency. *J Sleep Res* 2018;27(3):e12630. [PubMed: 29159867]
37. Hastert TA, Ruterbusch JJ, Beresford SA, Sheppard L, White E. Contribution of health behaviors to the association between area-level socioeconomic status and cancer mortality. *Soc Sci Med* 2016;148:52–58. [PubMed: 26650930]
38. Schwartsburd PM. Chronic inflammation as inductor of pro-cancer microenvironment: pathogenesis of dysregulated feedback control. *Cancer Metastasis Rev* 2003;22(1):95–102. [PubMed: 12716041]
39. Kushner I, Rzewnicki D, Samols D. What does minor elevation of C-reactive protein signify? *Am J Med* 2006;119(2):166 e117–128.
40. Babayan A, Pantel K. Advances in liquid biopsy approaches for early detection and monitoring of cancer. *Genome Med* 2018;10(1):21. [PubMed: 29558971]
41. Heitzer E, Perakis S, Geigl JB, Speicher MR. The potential of liquid biopsies for the early detection of cancer. *NPJ Precis Oncol* 2017;1(1):36. [PubMed: 29872715]
42. Santarpia M, Liguori A, D'Aveni A, et al. Liquid biopsy for lung cancer early detection. *J Thorac Dis* 2018;10(Suppl 7):S882–S897. [PubMed: 29780635]
43. Lin LY, Yang L, Zeng Q, et al. Tumor-originated exosomal lncUEGC1 as a circulating biomarker for early-stage gastric cancer. *Mol Cancer* 2018;17(1):84. [PubMed: 29690888]
44. Widschwendter M, Zikan M, Wahl B, et al. The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer. *Genome Med* 2017;9(1):116. [PubMed: 29268796]
45. Widschwendter M, Evans I, Jones A, et al. Methylation patterns in serum DNA for early identification of disseminated breast cancer. *Genome Med* 2017;9(1):115. [PubMed: 29268762]
46. Pimienta M, Edderkaoui M, Wang R, Pandol S. The Potential for Circulating Tumor Cells in Pancreatic Cancer Management. *Front Physiol* 2017;8:381. [PubMed: 28626429]
47. Rana A, Zhang Y, Esfandiari L. Advancements in microfluidic technologies for isolation and early detection of circulating cancer-related biomarkers. *Analyst* 2018.
48. Ferrie JE, Kumari M, Salo P, Singh-Manoux A, Kivimaki M. Sleep epidemiology--a rapidly growing field. *Int J Epidemiol* 2011;40(6):1431–1437. [PubMed: 22158659]
49. Grandner MA, Malhotra A. Sleep as a vital sign: why medical practitioners need to routinely ask their patients about sleep. *Sleep Health* 2015;1(1):11–12. [PubMed: 27840846]
50. Carroll JE, Irwin MR, Stein Merkin S, Seeman TE. Sleep and multisystem biological risk: a population-based study. *PLoS One* 2015;10(2):e0118467. [PubMed: 25714703]
51. Cho HJ, Irwin MR. Is Inflammation a Link Between Self-Reported Health and Infectious Disease Risk? *Psychosom Med* 2015;77(9):956–958. [PubMed: 26560415]

Figure 1.
Original Perspective

Figure 2.
Revised Perspective